Referenslitteratur för:

Referenslitteratur för produkten Femicur och indikationen PMS
 
  FÖRFATTARE OCH TIDSKRIFT
PUBLICERAD
HÄMTA PDF
       
  Referenser till Femicur och PMS    
       
  1. Abraham GE.
Premenstrual tension.
Year Book, Medical Publishers, Inc., USA, 1981.
1981
  
  2. Abraham GE.
Nutritional factors in the etiology of the premenstrual tension syndromes.
J Reprod Med 28: 446; 1983.

 1983
  
  3. Abt K.
Descriptive data analysis; a concept between confirmatory and exploratory data analysis.
Meth Inform 26: 77-88; 1987.

 1987
  
  4. Andersch B, Svensson A, Hansson L.
Pre-eclampsia, hypertension and the premenstrual tension syndrome.
Int J Gynaecol Obstet 32(2): 123-7, 1990.

 1990 Hämta här
  5. Andersch B, Hahn L.
Progesterone treatment of premenstrual tension – a double blind study.
J Psychosom Res 29(5): 489-93; 1985.

 1985
 Hämta här
  6. Becker H.
Unterdrückung der Prolaktin-Sekretion als ein Wirkprinzip eines Agnus castus-haltigen Kombinationsarzneimittels.
TW Gynäkologie 6: 396-399; 1991.

 1991
  
  7. Berger D.
Vitex agnus castus: Unbedenklichkeit und Wirksamkeit beim Prämenstruellen Syndrom; Wirkprinzipen und Wirkmechanismen eines neu entwickelten Extraktes.
PhD thesis, Basel, Switzerland, 1998.

 1998
  
  8. Berger D, Burkard W, Schaffner, W Meier B.
Rezeptorbindungsstudien mit Extrakten und daraus isolierten Substanzen.
In: Meier B, Hoberg F, eds.: Agni-casti-fructus. Neue Erkenntnisse zur Qualität und Wirksamkeit.
Z. Phytotherapie 20: 140-158; 1999.

 1999  
  9. Berger D, Schaffner W, Schrader E, Meier B, Brattstrom A.
Efficacy of Vitex agnus L. extract Ze 440 in patients with premenstrual syndrome (PMS).
Arch Gynecol Obstet 264: 150-153; 2000.

 2000
 Hämta här
  10. Baca-Garcia E, Diaz-Sastre C, Ceverino A, Garcia Resa E, Oquendo MA, Saiz-Riz J, de Leon J:
Premenstrual sytmptoms and luteal suicide attempts.
Eur Arch Psychiatry Clin Neurosci 254(5): 326-9; 2004.

 2004
 Hämta här
  11. Basoglu C, Cetin M, Semiz UB, Agargun MY, Ebrinc S.
Premenstrual exacerbation and suicidal behavior in patients with panic disorder.
Compr Psychiatry 41(2): 103-5; 2000.

 2000
 Hämta här
  12. Bixo M, Allard P, Bäckström T et al.:
Binding of [3H]paroxetine to serotonine uptake sites and of [3H]lysergic acid diethylamide to 5-HT2A receptors in platelets from women with premenstrual dysphoric disorder during gonadotropin releasing hormone treatment.
Psychoneuroendocrinology 26, 551-64; 2001.

 2001
 Hämta här
  13. Björn I, Bixo M, Nöjd KS et al.:
The impact of different doses of medroxyprogesterone acetate on mood symptoms in sequential hormonal therapy.
Gynecol Endocrinol 16, 1-8, 2002.

 2002
 Hämta här
  14. Blumenthal M.
German Federal Institute for Drugs and Medical Devices. Commission E.
The complete German Commision E monographs: therapeutic guide to herbal medicines. Austin, TX.
American Botanical Council, 1998.

 1998
  
  15. Borenstein J, Chiou CF, Dean B, Wong J, Wade S:
Estimating Direct and Indirect Costs of Premenstrual Syndrome.
J Occup Environ Med 47(1): 26-33, 2005.

 2005
 Hämta här
  16. Brown D.
Vitex agnus castus clinical monograph.
Quarterly Review of Natural Medicine 2: 111-121; 1994.

 1994
  
  17. Brugisser R, Burkard W, Simmen U, Schaffner W.
Untersuchungen an Opioid-Rezeptoren mit Vitex agnus-castus L.
In: Meier B, Hoberg E, eds.: Agni-casti-fructus. Neue Erkenntnisse zur Qualität und Wirksamkeit.
Z. Phytotherapie 20: 140-158; 1999.

 1999
  
  18. Bäckström T, Andersson A, Andree L et al.:
Pathogenesis in menstrual cycle-linked CNS disorders.
Ann NY Acad Sci 1007, 42-53, 2003.

 2003
 Hämta här
  19. Bäckström T, Andree L, Birzniece V et al.:
The role of hormones and hormonal treatments in premenstrual syndrome.
CNS Drugs 17, 325-42, 2003.

 2003
 Hämta här
  20. Böhnert KJ, Hahn G.
Phytotherapie in Gynäkologie und Geburtshilfe: Vitex agnus castus (Keuschlamm).
Erfahrungsheilkunde 39: 494-502; 1990.

 1990  
  21. Carroll BJ, Steiner M.
The psychobiology of premenstrual dysphoria: the role of prolactin.
Psychoneuroendocrinol 3: 171-180; 1978.

 1978
  
  22. Casper RF, Powell AM.
Premenstrual syndrome: documentation by a linear analog scale compared with two descriptive scales.
Am J Obstet Gynecol 155: 862-867; 1986.

 1986
  
  23. Christie S, Walker AF.
Vitex agnus-castus L. 1. A review of its traditional and modern therapeutic use.
2. Current use from a survey of practitioners.
Eur J Herbal Med 3: 29; 1998.

 1998
  
  24. Christie S, Walker AF, Hicks SM et al.:
Flavonoid supplement improves leg health and reduces fluid retention in pre-menopausal women in a double-blind, placebo-controlled study.
Phytomedicine 11, 11-7; 2004.

 2004

 Hämta här
  25. Chuong CJ, Coulam CB.
Current views and the beta-endorphin hypothesis.
In: Gies LH, Kase NG, Berkowith C, eds.
The premenstrual syndromes. NewYork: Churchill Livingstone, pp. 75-95; 1988.

1988

  
  26. Coeugniet E.
Das Prämenstruelle syndrom (PMS) und seine Behandlung.
Ärztezeitschrift für Naturheilverfahren 9: 619-622; 1986.

1986

  
  27. Czygan FC, Mayer JG.
Vitex agnus-castus L., der oder das Keuschlamm. Ein kulturhistorischer essay.
Accessed online at www.klostermedizin.de/html/moenchspfeffer.html.

2005
  
  28. Dietrich M, Hinney B, Link M, Kuhn W, Wuttke W.
Latent Hyperprolactinemia as a cause of Mastodynia and Luteal Function Impairment.
V:th Int. Congr. Prolactin. Abstract page 89, 1988.

1988

  
  29. Dittmar F, Böhnert K, Peeters M, et al.
Premenstrual syndrome: treatment with a phytopharmaceutical.
Therapiewoche Gynäkol 5: 60-68; 1992.

 1992
  30. Dittmar FW, Loch EG, Wiesenauer M, eds.
Naturheilverfahren in der Freauenheilkunde, 2nd ed. Stuttgart.
Hippokrates Verlag, page 170, 1998.

 1998
  
  31. Domoney CL, Vashisht A, Studd JW:
Premenstrual syndrome and the use of alternative therapies.
Ann NY Acad Sci 997, 320-40; 2003.

 2003 Hämta här
  32. Endicott J, McLaughlin TP, Grudzinski AN:
Comparison of managed care charges among patients treated with selective serotonin reuptake inhibitors for premenstrual dysphoric disorder.
J Clin Psychiatry 64, 343-51; 2004.

 2003

 Hämta här
  33. Eriksson E, Andersch B, Ho HP, Landen M, Sundblad C.
Diagnosis and treatment of premenstrual dysphoria.
J Clin Psychiatry 63, Suppl 7:16-23; 2002.

 2002
 Hämta här
  34. Eriksson E, Andersch B, Hoi-Por H, Landén M, Sundblad C:
Serotoninupptagshämmare ger snabb lindring vid premenstruell dysfori.
Läkartidningen 98(34):3524-30; 2001.

 2001 Hämta här
  35. Eriksson E, Hedberg MA, Andersch B, Sundblad C.
The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome.
Neuropsychopharmacology 12(2): 167-76; 1995.

 1995
 Hämta här
  36. Eriksson E, Alling C, Andersch B, Andersson K, Berggren U.
Cerebrospinal fluid levels of monoamine metabolites. A preliminary study of their relation to menstrual cycle phase, sex steroids, and pituitary hormones in healthy women and in women with premenstrual syndrome.
Neuropsychopharmacology 11(3): 201-13; 1994.

 1994 Hämta här
  37. Eriksson E, Sundblad C, Lisjo P, Modigh K, Andersch B.
Serum levels of androgens are higher in women with premenstrual irritability and dysphoria than in controls.
Psychoneuroendocrinology 17(2-3): 195-204; 1992.

 1992 Hämta här
  38. Feldmann, HU, Albrecht M, Lamertz M, Böhnert, KJ.
Therapie bei Gelbkörperschwäche bzw. prämenstruellem Syndrom mit
Vitex-agnus-castus-Tinktur.
Sonderdruck aus Gyne 11: 1990.

 1990  
  39. Fikentscher H.
Ätiologie, Diagnose und Therapie der Mastopathie und Mastodynie. Erfahrungen bei der Behandlung mit Mastodyn.
Medizinische Klinik 72: 1327-1330: 1977.

1977  
  40. Freeman EW, Rickels K, Sondheimer SJ et al.:
Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder.
Am J Psychiatry 161:1511-6; 2003.

2004

 Hämta här
  41. Freeman EW.
Premenstrual syndrome and premenstrual dysphoric disorder: definitions and diagnosis.
Psychoneuroendocrinology 28, suppl. 3: 25-37, 2003.

 2003 Hämta här
  42. Gerhard I, Patek A, Monga B, Blank A, Gorkow C.
Mastodyn bei weiblicher Sterilität.
Komplementärmedizin 5: 272-278; 1998.

1998
  
  43. Gregl A.
Die konservative Therapie der Mastopathie (Mastodynie).
Die Medizinische Welt 30: 264-268; 1979.

1979  
  44. Gregl A.
Die konservative Therapie der Mastopathie.
Die Medizinische Welt 36: 242-246; 1985.

1985

  
  45. Gold JH.
Premenstrual dysphoric disorder. What is that?
JAMA 278: 1024; 1997.

1997  
  46. Hagers Handbuch der Pharm.
Praxis: Vitex agnus-castus.
5. Auflage, Springer, Berlin, Heidelberg, NewYork, pp. 1185-1198: 1995.

1995  
  47. Halaska M, Raus K, Beles P, Martan A, Paithner KG.
Treatment of cyclical mastodynia using an extract of Vitex agnus castus:
results of a double-blind comparison with placebo.
Ceska Gynekol 63: 388-392; 1998.

1998  
  48. Halbreich U, Kahn LS.
Treatment of premenstrual dysphoric disorder with luteal phase dosing of sertraline.
Expert Opin Pharmacother 4(11):2065-78, 2003.

 2003 Hämta här
  49. Halbreich U, Borenstein J, Pearlstein T, Kahn LS.
The prevalence, impairment, impact, and burden of premenstrual dysphoric
disorder (PMS/PMDD).
Psychoneuroendocrinoligy  28, suppl. 3: 1-23, 2003.

 2003 Hämta här
  50. Halbreich U.
The etiology, biology, and evolving pathology of premenstrual syndromes.
Pxychoneuroendocrinology  28, suppl. 3:55-99; 2003.

 		2003
 Hämta här
  51. Hobbs C.
The chaste tree. Vitex agnus castus.
Pharm History 23: 19-24; 1991.

1991
  
  52. Hsiao CC, Liu CY, Hsiao MC:
No correlation of depression and anxiety to plasma estrogen and progesterone levels in patients with premenstrual dysphoric disorder.
Psychiatry Clin Neurosci 58(6): 595-9; 2004.
2004 Hämta här
  53. Jarry H, Leonhardt S, Wuttke W, Behr B, Gorkow C.
Agnus castus als dopaminerges Wirkprinzip in Mastodynon.
Zeitschrift für Phytotherapie 12: 77-82; 1991.

 1991  
  54. Jarry H, Leonhardt S, Gorkow C, Wuttke W.
In vitro prolactin but not LH and FSH release is inhibited by compounds in extracts of Agnus castus: direct evidence for a dopaminergic principle by the dopamine receptor assay.
Exp Clin Endocrinol 102: 448-454; 1994.

1994
  
  55. Kartning T.
Vitex agnus castus - Mönchspfeffer oder Keuschlamm.
Zeitschrift für Phytotherapie 7: 119-122; 1986.

1986  
  56. Kubista E, Müller G, Spona J.
Behandlung der Mastopathie mit zyklischer Mastodynie: Klinische Ergebnisse und Hormonprofile.
Gynäkologische Rundschau 26: 65-79; 1986.

1986  
  57. Kustrak D, Kuftinec J, Blazevic N.
The Composition of the essential Oil of Vitex agnus castus.
Planta Medica 56: Suppl 1: A681; 1992

 1992  
  58. Landen M, Eriksson O, Sundblad C, Andersch B, Naessen T, Eriksson E.
Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placebo.
Psychopharmacology (Berl). 155(3): 292-8; 2001.

 2001 Hämta här
  59. Lauritzen C, Reuter HD, Repges R, Böhnert KJ, Schmidt U.
Treatment of premenstrual tension syndrome with Vitex angus castus. Controlled double-blind study versus pyridoxine.
Phytomedicine 4: 183-189; 1997.

 1997  
  60. Levin AM.
Premenstrual syndrome: a new concept in its pathogenesis and treatment.
Med Hypotheses 62(1): 130-2; 2004.

 2004 Hämta här
  61. Liebl A.
Behandlung des prämenstruellen Syndroms.
TherapieWoche Gynäkologie 5: Heft 2; 1992.

1992  
  62. Loch EG, Böhnert KJ, Peeters M, Schmidt U, Lamertz M.
Die Behandlung von Blutungsstörungen mit Vitex agnus castus-Tinktur.
Der Frauenarzt 32: 867-870; 1991.

 1991  
  63. Loch EG, Selle H, Boblitz N, Wüstenberg P.
Wirksamkeit und Sicherheit eines neuen Vitex agnus castus-Präparates (Femicur Kapseln) bei der Behandlung des Prämenstruellen Syndroms.
Abstractband Phytopharmakaforschung 2000, pp. 126-127; 1998.

 1998
  64. Loch EG, Selle H, Boblitz N.
Treatment of premenstrual syndrome with a phytopharmaceutical formulation containing Vitex agnus castus.
J Womens Health Gend Based Med 9: 315-320; 2000.

 2000 Hämta här
  65. Loew D, Gorkow C, Schrödter A, Rietbrock S, Merz PG, Schnieders M, Sieder C.
Zur dosisabhängigen Verträglichkeit eines Agnus castus-Spezialextraktes.
Zeitschrift für Phytotherapie 17: 237-243; 1996.

 1996  
  66. Loew D.
Aktualisiertes Wissenschaftliches Erkenntnismaterial zu "Vitex Agnus-castus" (Mönchspfeffer).
Kooperation Phytopharmaka 1997.

 1997  
  67. Massil H, O'Brien PMS.
Premenstrual syndrome.
British Medical Journal 293: 1289-1292; 1986.

 1986  
  68. Meier B, Berger D, Hoberg E, Sticher O, Schaffner W.
Pharmacological activities of Vitex agnus-castus extracts in vitro.
Phytomedicine 7: 373-381; 2000.

 2000  
  69. Mergner R.
Zyklusstörungen. Therapie mit einem Vitex-agnus-castus-haltigen Kombinationsarzneimittel.
Der Kassenarzt 7: 51-60; 1992.

 1992  
  70. Merz PG, Gorkow C, Schrodter A, Rietbrock S, Sieder C, Loew D, et al.
The effects of a special Agnus castus extract (BP1095E1) on prolactin secretion in healthy male subjects.
Exp Clin Endocrinol Diabetes 104: 447-453; 1996.

 1996  
  71. Meyl Ch.
Therapie des prämenstruellen Syndroms.
Therapeutikon 5: 518-525; 1991.

 1991  
  72. Milewicz A, Gejdel E, Sworen H, Sienkiewicz K, Jedrzejak J, Teucher T, et al.
Vitex agnus castus extract in the treatment of luteal phase defects due to latent hyperprolactinemia. Results of a randomized placebo-controlled double-blind study.
Arzneimittelforschung 43: 752-756; 1993.

 1993  
  73. Peters-Welter C, Albrecht M.
Menstrual abnormalities and PMS. Vitex agnus-castus in a study of application.
TherapieWoche Gynäkol 7: 49-52; 1994.

 1994  
  74. Propping D, Böhnert KJ, Peeters M, Albrecht M, Lamertz M.
Vitex agnus castus.
Therapeutikon 5: 581 ; 1991.

 1991  
  75. Rapkin A.  
A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder.
Psychoneuroendocrinology 28, suppl. 3: 39-53; 2003.

2003 Hämta här
  76. Roeder D.
Therapie von Zyklusstörungen mit Vitex agnus castus.
Zeitschrift für Phytotherapie 15: 157-163; 1994.

 1994  
  77. Roemheld-Hamm B.
Chasteberry
American Family Physician 72:821-824; 2005.

 2005 Hämta här
  78. Samochowiec L, Glaesmer R, Samochowiec J.
Einfluss von Möchspfeffer auf die Konzentration von beta-Endorphin im Serum weiblicher Ratten.
Ärztezeitschr Naturheilverfahren 39: 213-215; 1998.

 1998  
  79. Schellenberg R.
Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study.
BMJ 322: 134-137; 2001.

 2001 Hämta här
  80. Severino SK, Moline ML.
Premenstrual Syndrome. Identification and Management.
Drugs 49: 71-82, 1995.

 1995  
  81. Shuster J.
Black cohossh root? Chasteberry tree? Seizures!
Hospital Pharmacy 31: 1553-1554; 1996.

 1996  
  82. Sliutz G, Speiser G, Schultz AM, Spona J, Zeilinger R:
Agnus castus extracts inhibit prolactin secretion of rat pituitary cells.
Hormone Metabl Res 25: 253-255; 1993.

 1993  
  83. Steiner M, Haskett RF, Carroll BJ.
Premenstrual tension syndrome: the development of research diagnostic criteria and new rating scales.
Acta Psychiatr Scand 62: 177-190; 1980.

 1980  
  84. Sundblad C, Modigh K, Andersch B, Eriksson E.
Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial.
Acta Psychiatr Scand 85(1): 39-47; 1992.

1992
 Hämta här
  85. Sundblad C, Wikander I, Andersch B, Eriksson E.
A naturalistic study of paroxetine in premenstrual syndrome: efficacy and side-effects during ten cycles of treatment.
Eur Neuropsychopharmacol 7(3): 201-6; 1997.

 1997 Hämta här
  86. Turner S, Mills S.
A double-blind clinical trial on a herbal remedy for premenstrual syndrome:
a case study.
Complement Ther Med 1: 73-77; 1993.

1993  
  87. Upton R.
Chaste tree fruit: Vitex agnus-castus: standards of analysis, quality control, and therapeutics.
American Herbal Pharmacopoeia and Therapeutic Compendium, 2001.

2001  
  88. Westphal LM, Polan ML, Trant As, Mooney SB.
A nutritional supplement for improving fertility in women: a pilot study.
J Reprod Med 49: 289-293; 2004.

 2004 Hämta här
  89. Wikander I, Sundblad C, Andersch B, Dagnell I, Zylberstein D, Bengtsson F, Eriksson E.
Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle?
J Clin Psychopharmacol 18(5): 390; 1998.

 1998 Hämta här
  90. Wuttke W.
Dopaminergic action of extracts of Agnus Castus.
Forschende Komplementarmedizen 3: 329-330; 1996.

 1996  
  91. Wuttke W, Gorkow Ch, Jarry H.
Dopaminergic Compounds in Vitex Agnus Castus.
In: Loew D, Rietbrock N, eds.: Phytopharmaka in Forschung und klinischer Anwendung. Steinkopf, Darmstadt, pp 81-91, 1995.

 1995  
  92. Wuttke W, Splitt G, Gorkow C, Sieder C.
Behandlung zyklusabhängiger Brustschmerzen mit einem Agnus castus-haltigen Arzneimittel.
Geburtsh und Frauenheilk 57: 4-14; 1997.

 1997  
  93. Wuttke W, Jarry H, Christoffel V, Spengler B, Seidlová-Wuttke D.
Chaste tree (Vitex agnus-castus) - Pharmacology and
Clinical indications.
Phytomedicine 10: 348 - 357; 2003.

 2003
 Hämta här
  94. Yonkers KA, Perlstein T, Rosenheck RA.
Premenstrual disorders: bridging research and clinical reality.
Arch Women Ment Health 6 (4): 287-92; 2003.

 2003
 Hämta här
 

95. Zwaving JH, Bos R.
Composition of the Essential Fruit Oil of Vitex agnus castus.
Planta Medica 62: 83-84; 1996.

1996